Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal Cancers
Highlight
- Identification of an optimal CA19-9-specific CAR T construct with robust expansion and cytotoxicity against pancreatic ductal adenocarcinoma (PDAC).
- Sustained and selective killing of CA19-9-positive tumor cells demonstrated in vitro, in patient-derived organoids, and multiple in vivo models.
- Proof of efficacy in immunocompetent murine PDAC models including primary and metastatic disease.
- Demonstrated anti-tumor activity extends beyond PDAC to include CA19-9-expressing gastrointestinal malignancies such as colon, stomach, esophageal, and biliary tract cancers.
Study Background and Clinical Context
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.